Despite the impact of the ongoing COVID-19 pandemic, the European urological device market will grow marginally through 2029. Revenue growth will be driven by ongoing product innovation and an increasing aging population and an associated rise in cases of urological diseases such as UI, stones, BPH, prostate and bladder cancer, and ED; however, the market will be negatively affected in the short term by the global COVID-19 pandemic, limited capital equipment budgets among European health care facilities, and prevailing preferences for established treatment methods will hinder the adoption of newer, premium-priced technology to some degree, hampering overall market growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in France, Germany, Italy, Spain, and the UK across a 10-year period.

The COVID-19 pandemic will negatively impact the European urological device market. 

Which types of procedures and device segments will be most impacted?

At what pace is the urological device market expected to recover?

The strong cost constraints experienced by health care facilities in Europe will hinder the adoption of premium-priced urological devices.

Which devices will be most impacted by this trend?

What strategies will urological device companies use to remain competitive despite these challenges?

Physician preferences for certain procedures will drive growth in multiple device segments.

Which procedures are urologists more inclined to perform?

Which device segments will be impacted as a result?

The rising adoption of flexible endoscopy in this market will spur growth in multiple device segments.

How many flexible cystoscopes and flexible ureteroscopes will be sold in this region?

How will the stone management device market be impacted by growth in flexible endoscope use?

How will the growing use of flexible endoscopy impact other endoscope market segments?

Table of contents

  • Urological Devices - Market Insights - Europe

Author(s): Sumit Jain, MS Pharm

Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.